What should an 84‑year‑old woman do with a blood pressure of 172/80 mm Hg?

Management of Blood Pressure 172/80 mmHg in an 84-Year-Old Woman

Immediate Recommendation

This 84-year-old woman requires antihypertensive treatment immediately, starting with a single agent—preferably a dihydropyridine calcium channel blocker (amlodipine 2.5–5 mg daily) or a thiazide-like diuretic (chlorthalidone 12.5 mg or indapamide 1.25 mg daily)—with a target blood pressure of <140/90 mmHg minimum, ideally approaching 130/80 mmHg if well tolerated. 1, 2

---

Blood Pressure Classification and Treatment Threshold

• A blood pressure of 172/80 mmHg represents stage 2 hypertension (systolic ≥160 mmHg) that warrants immediate pharmacologic intervention regardless of age. 1, 2
• The European Society of Cardiology 2024 guidelines explicitly state that patients ≥80 years with office BP ≥140/90 mmHg should be considered for treatment, and those with systolic ≥160 mmHg (grade 2 hypertension) demand prompt therapy because of substantial cardiovascular risk. 1
• All individuals aged 80–85 years have sufficiently high 10-year cardiovascular risk to merit treatment at the ≥140/90 mmHg threshold, irrespective of calculated risk scores. 1

---

Target Blood Pressure Goals

• The primary target is <140/90 mmHg as a minimum acceptable goal for functionally independent adults ≥80 years. 1, 2
• For robust, non-frail patients who tolerate therapy well, a stricter target of 120–129 mmHg systolic is reasonable and supported by the 2024 ESC guidelines. 1
• The European Society of Cardiology recommends systolic BP reduction to between 140–150 mmHg in those ≥80 years with initial systolic ≥160 mmHg, though <140 mmHg is preferred when tolerated. 2
• Diastolic pressure should be maintained ≥60 mmHg to preserve coronary perfusion, especially in elderly patients with coronary artery disease. 2, 3

---

Pre-Treatment Assessment

Frailty and Orthostatic Hypotension Screening

• Assess frailty using validated clinical tools before setting BP targets; moderate-to-severe frailty warrants individualized, less aggressive goals regardless of chronological age. 1, 2
• Measure blood pressure after 5 minutes seated/lying, then at 1 minute and 3 minutes after standing to detect orthostatic hypotension, which is common in this age group. 1, 2
• Symptomatic orthostatic hypotension should prompt reconsideration of combination therapy and a more cautious approach. 1

Confirmation of True Hypertension

• Verify elevated readings with home blood pressure monitoring (≥135/85 mmHg) or 24-hour ambulatory monitoring (≥130/80 mmHg) to exclude white-coat hypertension before escalating therapy. 1

---

First-Line Pharmacologic Therapy

Preferred Initial Agent: Dihydropyridine Calcium Channel Blocker

• Start amlodipine 2.5–5 mg once daily; dihydropyridine CCBs are specifically recommended for patients ≥85 years and those with frailty because they do not cause bradycardia and are well tolerated. 1, 2
• Begin with the low dose (2.5 mg) and titrate gradually to minimize vasodilatory side effects such as peripheral edema. 1
• Calcium channel blockers are safe in patients with asthma, COPD, or isolated systolic hypertension without other compelling indications. 1

Alternative Initial Agent: Thiazide-Like Diuretic

• Chlorthalidone 12.5 mg once daily (preferred) or indapamide 1.25 mg daily are equally acceptable first-line options. 1, 2
• Thiazide-like diuretics are particularly effective in elderly patients and those with volume-dependent hypertension. 1
• Limit chlorthalidone to 12.5 mg daily in older patients; doses above this markedly increase hypokalemia risk (3-fold higher) and hospitalization rates (3.06-fold higher) without proportional BP benefit. 1, 2
• Hypokalemia below 3.5 mEq/L eliminates cardiovascular protection and increases sudden death risk. 1

When to Use ACE Inhibitors or ARBs First-Line

• For patients with diabetes mellitus, chronic kidney disease with albuminuria, heart failure, or post-myocardial infarction, an ACE inhibitor (lisinopril 5–10 mg daily) or ARB (losartan 25–50 mg daily) becomes the preferred first-line agent. 1

---

Monotherapy vs. Combination Therapy in the Very Elderly

• Prefer monotherapy initially in patients >80 years or those who are frail to limit adverse effects and allow careful titration. 1, 2
• For functionally independent, non-frail patients aged 80–85 years with stage 2 hypertension (≥160/100 mmHg), dual therapy may be initiated immediately using a single-pill combination of a RAS blocker plus either a CCB or thiazide diuretic. 1

---

Escalation to Dual and Triple Therapy

Adding a Second Agent (If BP Remains ≥140/90 mmHg After 2–4 Weeks)

• Add a complementary-class agent: CCB + RAS inhibitor or RAS inhibitor + thiazide diuretic. 1
• The European Society of Cardiology recommends fixed-dose single-pill combinations to improve adherence in elderly patients. 1

Triple Therapy (If Dual Therapy Fails)

• Introduce a thiazide-like diuretic (chlorthalidone 12.5 mg or indapamide 1.25 mg daily) if BP remains ≥140/90 mmHg on dual therapy. 1
• The combination of RAS blocker + CCB + thiazide diuretic is the guideline-endorsed regimen for resistant hypertension. 1

Fourth-Line Therapy (Resistant Hypertension)

• If BP stays ≥140/90 mmHg despite optimized triple therapy, add spironolactone 25–50 mg daily as the preferred fourth-line agent, which provides additional reductions of approximately 20–25/10–12 mmHg. 1

---

Medications to Avoid or Use Cautiously

• Beta-blockers should not be used as first-, second-, or third-line agents unless a compelling indication exists (heart failure, recent MI, angina, atrial fibrillation), because they are less effective for stroke prevention in the elderly. 1, 2
• Alpha-blockers are discouraged due to increased fall risk in older adults. 1
• Avoid combining two RAS-blocking agents (ACE inhibitor + ARB) because of increased adverse events (hyperkalemia, acute kidney injury) without added cardiovascular benefit. 1

---

Monitoring and Follow-Up

Initial Monitoring (First 2–4 Weeks)

• Re-measure blood pressure 2–4 weeks after starting therapy or any dose adjustment. 1, 2
• When a thiazide diuretic is initiated, check serum potassium and creatinine 2–4 weeks later to detect hypokalemia or renal function changes. 1, 2

Ongoing Monitoring

• Assess for orthostatic hypotension at each visit by measuring BP in both sitting and standing positions. 1, 2
• Electrolytes (potassium, sodium, magnesium) and renal function should be re-checked every 3–6 months during chronic diuretic therapy. 4
• Aim to achieve target BP within 3 months of initiating or modifying therapy. 1

Long-Term Follow-Up

• Once BP is controlled, schedule at least annual reviews of blood pressure and cardiovascular risk factors. 1

---

Lifestyle Modifications (Adjunct to Pharmacotherapy)

• Sodium restriction to <2 g/day (≈5 g salt) can lower systolic BP by 5–10 mmHg and enhances the efficacy of all antihypertensive classes. 1, 2
• Target a body-mass index of 20–25 kg/m² through weight management when overweight. 1
• Regular aerobic exercise appropriate to functional capacity and age (≥30 minutes most days, ≈150 minutes/week moderate intensity) lowers BP by approximately 4/3 mmHg. 1
• Limit alcohol intake to <100 g/week (≈7 standard drinks). 1, 2

---

Lifelong Treatment Principle

• Antihypertensive treatment should be continued lifelong, even beyond age 85, as long as it is tolerated; discontinuation increases cardiovascular risk. 1, 2
• The 2024 ESC guidelines explicitly state it is incorrect to withhold treatment solely on the basis of chronological age; decisions should be guided by functional status and frailty. 1
• Patients who were started on treatment when younger should not have their therapy back-titrated when they reach age 80. 5

---

Common Pitfalls to Avoid

• Do not withhold antihypertensive therapy solely because of age; the ESC 2024 guidelines explicitly recommend continuation beyond age 85 when tolerated. 1, 2
• Do not increase the dose of a single agent before adding a second drug from a different class; combination therapy is more effective than monotherapy dose escalation. 1
• Do not delay treatment intensification when hypertension remains uncontrolled (≥140/90 mmHg); prompt action within 2–4 weeks is required to reduce cardiovascular risk. 1
• Do not assume treatment failure without first confirming medication adherence and excluding secondary causes of hypertension (primary aldosteronism, renal artery stenosis, obstructive sleep apnea). 1
• If achieving a systolic target of 120–129 mmHg is not feasible due to intolerance, adopt the "as low as reasonably achievable" (ALARA) principle for systolic BP, with a minimum acceptable target of <140/90 mmHg. 1

---

Special Considerations for This Patient

Isolated Systolic Hypertension

• This patient has isolated systolic hypertension (systolic 172 mmHg, diastolic 80 mmHg), which is extremely common in adults >70 years and results from arterial stiffening. 5, 6
• The ESC/ESH guidelines discuss isolated systolic hypertension in detail, recommending a goal of <140 mmHg systolic based on three randomized prospective trials (SHEP, HYVET, Syst-Eur). 5
• The diastolic pressure of 80 mmHg is acceptable and should be maintained ≥60 mmHg during treatment. 2, 3

Stroke Prevention

• Hypertension is a major risk factor for both ischemic and hemorrhagic stroke in the elderly. 6
• The SHEP trial (63% women, mean age 72 years) demonstrated that treatment significantly reduced stroke incidence (5.5% vs. 8.2% with placebo) in elderly women with isolated systolic hypertension. 5
• Treatment of hypertension in women is primarily driven by stroke reduction, with a meta-analysis of 20,802 women showing significant benefit for stroke and major CVD events. 5

Gender-Specific Considerations

• Women aged 55–65 years who are free of hypertension at baseline have a 90% lifetime risk of developing hypertension, with approximately 40% developing stage 2 hypertension (≥160/100 mmHg) regardless of treatment. 5
• Treating to SBP <140 mmHg provides greater public health protection against CVD among older women with little evidence of serious harm. 5

---

Evidence Quality and Guideline Strength

• The 2024 ESC recommendations (Class I, Level A) underpin the ≥140/90 mmHg initiation threshold and the promotion of lifelong therapy in the very elderly. 1
• The HYVET study (2008) demonstrated clinical benefits and cost-effectiveness of treating hypertension in people aged ≥80 years. 5
• The SPRINT trial demonstrated that intensive BP control safely reduced CVD risk in those >65, >75, and >80 years without increasing falls, orthostatic hypotension, or other serious adverse effects. 1